vs
Side-by-side financial comparison of Caris Life Sciences, Inc. (CAI) and Celcuity Inc. (CELC). Click either name above to swap in a different company.
Caris Life Sciences is a leading precision medicine biotech company specializing in advanced molecular profiling for oncology. It provides actionable genomic and molecular insights to oncologists to personalize cancer treatment plans, and partners with biopharmaceutical firms to accelerate novel cancer drug discovery and development, serving customers across North America, Europe, and key Asia-Pacific markets.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $216.8M | — | ||
| Q2 25 | $181.4M | — | ||
| Q3 24 | $101.6M | — | ||
| Q2 24 | $100.0M | — |
| Q3 25 | $24.3M | — | ||
| Q2 25 | $-71.8M | — | ||
| Q3 24 | $-67.7M | — | ||
| Q2 24 | $-66.2M | — |
| Q3 25 | 15.1% | — | ||
| Q2 25 | -9.9% | — | ||
| Q3 24 | -59.9% | — | ||
| Q2 24 | -67.0% | — |
| Q3 25 | 11.2% | — | ||
| Q2 25 | -39.6% | — | ||
| Q3 24 | -66.6% | — | ||
| Q2 24 | -66.2% | — |
| Q3 25 | $0.08 | — | ||
| Q2 25 | $-7.97 | — | ||
| Q3 24 | $-2.59 | — | ||
| Q2 24 | $-2.54 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
